Wei-neng Feng
Foshan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
Journal: Nature communications
Published: June 21, 2025
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease.
Journal: Clinical lung cancer
Published: October 09, 2024
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
Journal: Cancer cell
Published: February 05, 2024
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients.
Journal: Therapeutic advances in medical oncology
Published: December 12, 2022
Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
Journal: World journal of surgical oncology
Published: May 08, 2022
Multiple-line Chemotherapy and Tyrosine Kinase Inhibitor Treatment in Patients with Advanced Lung Cancer.
Journal: Combinatorial chemistry & high throughput screening
Published: September 26, 2018
Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients.
Journal: Translational oncology
Published: December 16, 2017
Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stage III and IVA-B nasopharyngeal carcinoma.
Journal: Asian Pacific journal of cancer prevention : APJCP
Published: May 29, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026